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Abstract 
Background: Malaria‑associated acute respiratory distress syndrome (MA‑ARDS) is a potentially lethal complica‑
tion of clinical malaria. Acute lung injury in MA‑ARDS shares features with ARDS triggered by other causes, including 
alveolar inflammation and increased alveolar‑capillary permeability, leading to leak of protein‑rich pulmonary oedema 
fluid. Mechanisms and physiologic alterations in MA‑ARDS can be examined in murine models of this syndrome. 
Integrin αDβ2 is a member of the leukocyte, or β2 (CD18), sub‑family of integrins, and emerging observations indicate 
that it has important activities in leukocyte adhesion, accumulation and signalling. The goal was to perform analysis of 
the lungs of mice wild type C57Bl/6 (aD
+/+) and Knockout C57Bl/6 (aD
−/−) with malaria‑associated acute lung injury to 
better determine the relevancy of the murine models and investigate the mechanism of disease.
Methods: C57BL/6 wild type (aD
+/+) and deficient for CD11d sub‑unit (aD
−/−) mice were monitored after infection with 
105 Plasmodium berghei ANKA. CD11d subunit expression RNA was measured by real‑time polymerase chain reac‑
tion, vascular barrier integrity by Evans blue dye (EBD) exclusion and cytokines by ELISA. Protein and leukocytes were 
measured in bronchoalveolar lavage fluid (BALF) samples. Tissue cellularity was measured by the point‑counting tech‑
nique, F4/80 and VCAM‑1 expression by immunohistochemistry. Respiratory function was analysed by non‑invasive 
BUXCO and mechanical ventilation.
Results: Alveolar inflammation, vascular and interstitial accumulation of monocytes and macrophages, and dis‑
rupted alveolar‑capillary barrier function with exudation of protein‑rich pulmonary oedema fluid were present in P. 
berghei‑infected wild type mice and were improved in αDβ2‑deficient animals. Key pro‑inflammatory cytokines were 
also decreased in lung tissue from αD
−/− mice, providing a mechanistic explanation for reduced alveolar‑capillary 
inflammation and leak.
Conclusions: The results indicate that αDβ2 is an important inflammatory effector molecule in P. berghei‑induced 
MA‑ARDS, and that leukocyte integrins regulate critical inflammatory and pathophysiologic events in this model of 
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Background
Malaria is an infectious disease that is caused by the 
genus Plasmodium sp. transmitted through the bite of 
Anopheles mosquitoes that are infected with protozoan 
parasites and is a major public health problem  40  % or 
more of the global population is at risk for malaria [1]. 
The pathogenesis of malaria is multi-factorial, with both 
host and Plasmodium sp. factors playing critical roles 
[2, 3]. Nevertheless, the mechanisms responsible for the 
high morbidity and mortality of severe cases of malaria 
remain poorly understood. In endemic areas, many 
infections in semi-immune population present as an 
uncomplicated febrile illness. In more severe cases, non-
immune individuals may exhibit a number of syndromes 
including severe anaemia (SA), cerebral malaria (CM) or 
respiratory distress syndrome [4, 5].
Lung involvement in malaria has been described most 
often in non-immune individuals, with infection by 
Plasmodium falciparum [6–9], Plasmodium ovale [7, 
10, 11], Plasmodium vivax and Plasmodium malariae 
[6, 7, 12–16]. While the alveoli and airways can also be 
involved in mild infection [17], acute alveolar injury and 
acute respiratory distress syndrome (ARDS) are major 
sequelae of severe malaria and have significant morbid-
ity and mortality [3, 17–19]. Malaria-associated ARDS 
(MA-ARDS) has been reported in infection with all 
human malarial parasites, although the greatest number 
of cases is caused by P. falciparum and P. vivax [17, 20, 
21]. Patients with alveolar involvement in malaria have 
classically been reported to have pulmonary oedema, 
with recent recognition that the alveolar oedema is due 
to increased pulmonary capillary permeability [21–24]. 
In addition to altered alveolar-capillary barrier function 
with leak of protein-rich oedema fluid [3, 22–24], which 
is a cardinal manifestation of acute alveolar inflamma-
tion, alveolar involvement in human malaria has other 
significant inflammatory components, including leuko-
cyte accumulation [17, 21, 25–29]. Alveolar inflamma-
tion is also a fundamental feature of ARDS induced by 
bacterial sepsis, infectious pneumonia, aspiration of gas-
tric contents, major trauma, and other common ‘triggers’ 
[30]. A difference is that, in these more common etiolo-
gies of ARDS, alveolar injury is thought to be primarily 
caused by neutrophil- and platelet-dependent damage 
to endothelial and epithelial barriers of the alveolar-cap-
illary membrane [30, 31], whereas in MA-ARDS mono-
cytes and macrophages dominate in the inflammatory 
infiltrate [21, 25–29]. MA-ARDS has been modelled in 
studies utilizing mice and other animals, yielding mecha-
nistic insights and experimental correlates [21, 32–37]. 
There is evidence that lung injury in the murine model 
Plasmodium berghei ANKA strain [33, 34, 37, 38] is asso-
ciated with intravascular sequestration of parasitized red 
blood cells [33, 39], suggesting that it is a useful surrogate 
for human malarial disease [26, 40].
Integrins are cell surface heterodimers formed by non-
covalent association of α and β polypeptide chains (sub-
units). Integrins are widely expressed on mammalian 
cells and have multiple activities in cellular adhesion, 
migration, signalling, and fate [41, 42]. A sub-family of 
integrins, termed the β2, CD18, or leukocyte integrins, 
share a common β2 sub-unit and are expressed on circu-
lating and tissue leukocytes [43, 44]. Four α chains pair 
with the β2 peptide sub-unit to yield four leukocyte-
restricted integrins: αLβ2 (CD11a/CD18, LFA-1), αMβ2 
(CD11b/CD18, MAC-1, CR3), αXβ2 (CD11c/CD18), and 
αDβ2 (CD11d/CD18) [43, 44]. Leukocyte β2 integrins are 
required for host defence against many pathogens and for 
tissue surveillance and repair, as demonstrated by defi-
ciency syndromes that cause recurrent infections and 
impaired wound healing in humans and animals [44, 45]. 
In contrast, however, β2 integrin-mediated activities of 
leukocytes also contribute to tissue injury in a variety of 
inflammatory syndromes [46].
Integrin αDβ2, the most recently identified β2 integrin, is 
expressed on human and murine leukocytes, although its 
basal expression is different in man and mouse [47–51]. 
Integrin αDβ2 is expressed on tissue leukocytes in human 
inflammatory syndromes, including atherosclerosis [48], 
arthritis [52], and ARDS [51]. In rodents, there is evidence 
that αDβ2 can be induced on macrophages or monocytes 
in the spleen and liver [50], lung [53], and blood [54] in 
response to inflammatory challenge, and that αDβ2 con-
tributes to inflammatory tissue damage in experimen-
tal spinal cord and brain injury [55–57]. Previously, 
Miyazaki et  al. [50] found that genetic deletion of αD in 
mice, leading to deficiency of αDβ2, alters survival and 
systemic cytokine levels in mice infected with P. berghei 
without altering parasitaemia or anaemia. αDβ2 influences 
the pathogenesis of experimental cerebral malaria in P. 
berghei infection (unpublished studies). In this work was 
examined αDβ2 in lung involvement in P. berghei -infected 
animals and found that it influences key features of acute 
lung injury in this model of experimental MA-ARDS.
complicated malaria. Genetic deletion of integrin subunit αD in mice, leading to deficiency of integrin αDβ2, alters lung 
inflammation and acute lung injury in a mouse model of MA‑ARDS caused by P. berghei.
Keywords: Integrin αDβ2, Acute lung injury, Acute respiratory distress syndrome, Inflammation, Malaria
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Methods
Mouse models of malaria
The Animal Welfare Committee of the Oswaldo Cruz 
Institute approved the experiments in these studies 
under the licence number L-033/09. Wild Type (aD+/+) 
and C57BL/6 deficient for CD11d integrin (aD−/−) mice 
[50] weighing 20–25 g were obtained from the Oswaldo 
Cruz Foundation breeding unit and used throughout 
the study. The animals were kept at constant tempera-
ture (25 °C) with free access to food and water in a room 
with a 12-h light/dark cycle. C57BL/6 mice were infected 
by an ip injection of 200  mL of PBS containing 105 red 
blood cell (RBC) parasitized with the Pasteur strain of P. 
berghei ANKA [58]. All analyses were performed at day 
7 post-infection. Between 90 and 100 % of infected mice 
developed lung injury and cerebral malaria (data about 
cerebral malaria not yet published).
Bronchoalveolar lavage fluid analysis
Infected and uninfected mice were euthanized using iso-
flurane (Abott Labs do Brasil LTDA) and bronchoalveo-
lar lavage fluid (BALF) from both lungs was performed 
by instillation and aspiration of 1  mL of cold 1× phos-
phate buffered saline (PBS) [33]. Total leukocytes (diluted 
in Turk’s 2 % acetic acid fluid) were counted using Neu-
bauer chamber hemocytometer. Differential counts were 
performed in cytospins (Cytospin3, Shandon, CA, USA) 
and stained by the May-Grünwald-Giemsa method. The 
BALF was spun at 350 g at room temperature for 5 min, 
and the supernatant was removed and stored at −80  °C 
for further analyses. BALF total protein concentration 
was measured using a BCA protein assay kit (Thermo 
Scientific, Waltham, MA, USA).
Lung permeability
Mice were injected intravenously (iv) with 0.2 mL of 2 % 
Evans Blue dye (Sigma-Aldrich Brasil LTDA, São Paulo, 
Brazil) and were sacrificed 1  h later. Before collecting 
lung, mice were perfused with PBS 1X. The lungs were 
collected and placed in 2  mL of formamide (VETEC 
Química Fina LTDA, Duque de Caxias, RJ, Brazil) at 
37 °C, overnight to extract Evans Blue dye from the tissue 
[59]. Absorbance was measured at λ = 620 nm (Molec-
ular Devices Spectra Max 190, Sunnyvalle, CA, USA). 
Evans Blue dye concentration was calculated from a 
standard curve and is expressed as mg of Evans Blue dye 
per lung tissue.
Lung histology
Before collecting lung, mice were perfused with PBS 1X. 
Lungs from infected and uninfected mice were inflated 
by injecting 1.0  mL of 10  % buffered formalin through 
the same catheter used to perform BALF. Lungs were 
removed fixed in formalin and embedded in paraffin. 
Lungs sections of 5-mm thickness were stained with 
haematoxylin-eosin [59]. Analysis of tissue sections was 
performed in a Olympus BX41 microscope (Melville, NY, 
USA) at a magnification of ×200. The number of mono-
nuclear cells in lung tissue was determined by the point-
counting technique across 20 random, non-coincidents 
microscopic fields in an Olympus BX41 microscope at a 
magnification of ×1000 [60].
Cytokine determinations
Before collecting lung, mice were perfused with PBS 1X. 
Lungs of infected and uninfected mice were excised and 
homogenized in 750  mL of a protease inhibitor cock-
tail (Complete, mini EDTA-free Roche Applied Science, 
Mannheim, Germany) for 30 s, using a Ultra-Turrax Dis-
perser T-10 basic (IKA-Guangzhou, China). Homogen-
ates were stored at −20 °C, for analysis of cytokines using 
a commercial ELISA kit according to the manufacturer’s 
instructions (R&D Systems Duo set kits, Minneapolis, 
USA).
Quantitative RT‑PCR
Before collecting lung and spleen, mice were perfused 
with PBS 1X. Extraction of total RNA from lungs and 
spleen was performed using TRIzol® (Invitrogen, Carls-
bad, CA, USA), according to the manufacturer’s instruc-
tions. After extraction, RNA concentration and quality 
were determined using a NanoDrop 2000 spectropho-
tometer (Thermo Scientific). One microgram of total 
RNA was reverse-transcribed to single-strand cDNA 
using the SuperScript First-Stand (Invitrogen). aD tran-
scripts in the cDNA pool obtained from the reverse 
transcriptase reaction were quantified by real-time 
quantitative fluorogenic PCR. TaqMan Universal PCR 
Master Mix (Applied Biosystems, Foster City, CA, USA) 
was used to quantify gene expression according to the 
manufacturer’s instructions. RNA expression levels 
were calculated using the Data Assist Software v.3, and 
normalized against the expression levels of the house-
keeping gene hypoxanthine guanine phosphoribosyl 
transferase (HPRT) [50]. The primers used were as fol-
lows: aD (TaqMan-murine-Mm01159115_m1) and HPRT 
(TaqMan-murine- Mm01545399_m1).
Immunofluorescence
The primary monoclonal antibodies used in immuno-
fluorescence reactions were VCAM-I (rat anti-Mouse 
CD106, eBioscience, San Diego, CA, USA) and negative 
control (rat anti-IgG2b, Bioscience). Before collecting 
lung, mice were perfused with PBS 1X. Lung tissues from 
infected and uninfected mice aD+/+ and aD−/− were frozen 
in tissue freezing medium (TBS™, Triangle Biomedical 
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Science, Inc, Durham, NC, USA) and 10-mm cryostat 
sections were deposited on 3-aminopropyl triethoxysi-
lane (Sigma-Aldrich) prepared slides. The sections were 
then fixed in 2  % paraformaldehyde and permeabilized 
with 0.01  % Triton X-100 (Sigma) for 10  min. Sections 
were then blocked with 10  % normal goat serum, for 
40  min and subsequently incubated with primary anti-
body overnight at 4  °C. Alexa 546-conjugated goat anti-
rat antibody was applied 1/1000 dilution and incubated 
for 40 min. The sections were then layered with anti-
fade medium conjugated with DAPI (Vectashield, Vec-
tor Laboratories, Burlingame, CA, USA). The slides were 
analysed by confocal laser scanning microscopy on Zeiss 
LSM 510-META (Jena, Germany).
Immunohistochemistry
Primary monoclonal antibodies used in immunohisto-
chemistry reactions were F4/80 (MCA497-Serote c; anti-
rat) and IgG-HRP (STAR72-Serotec; goat anti rat) were 
also used in immunohistochemistry reactions. After 
deparaffinization, the sections were hydrated with TBS 
(Tris/HCl 0.05  M +  NaCl 0.5  M, pH 7.6), and H2O2 in 
methanol 3  % was add for 15  min. Slides were washed 
with TBS and blocked with Tris–HCl  +  BSA 5  % for 
2  h and subsequently incubated with primary antibody 
diluted Tris–HCl + BSA 1 % for 12 h at 4 °C. After incu-
bation, the slides were washed with TBS. The secondary 
antibody HRP-conjugated was diluted in Tris–HCl and 
incubated for 2 h. The revealed was made with 3-amino-
9-ethylcarbazole (AEC) for 15  min. The slides were 
washed with distilled water, counterstained with haema-
toxylin of Mayer and mounted in an aqueous medium-
containing gelatin. The slides were analysed using a 
Olympus BX41 microscope at a magnification of ×200.
Airway hyperreactivity analysis
Airway hyperreactivity (AHR) [61] was analysed in 
infected and uninfected mice using non-invasive whole-
body plethysmography (Buxco, Sharon, Connecticut, CT, 
USA) 7  days’ post infection. AHR was measured after 
aerosolization of 1× PBS followed by increasing concen-
trations of methacholine (0, 171, 6, 25  mg/mL; Sigma-
Aldrich) for 7 min into the chamber. AHR was expressed 
as an average enhanced pause [38]. There was an interval 
of 10 min between each aerosol exposure and within this 
period of time the Penh values had returned to baseline.
Lung pressure/volume analysis in mechanically ventilated 
mice
Pressure/volume (PV) relationships was examined in 
mechanically ventilated wild type and αD−/− uninfected 
and PbA-infected in mice. After 40  s of stabilization 
period under baseline settings (VT of 8–10 mL/kg, RR of 
80 breaths/min, ratio I:E of 1:1 and PEEP of 2  cm H2O), 
RR was decreased to 6 breaths/min, PEEP of 0 cmH2O, 
I:E ratio set at 4:1, VT was increased to 25–30 mL/kg and 
three PV curves were obtained. Airway pressure was 
continuously measured with a differential pressure trans-
ducer (UT-PDP-50, SCIREQ, Canada) at the distal end 
of the endotracheal tube (ETT). Airflow was measured 
with a heated-controlled pneumotachograph connected 
to a pressure transducer and positioned between the ETT 
and the Y-piece of the mechanical ventilator. Paw and 
airflow signals were low-pass filtered at 30  Hz, digitized 
at 1000  Hz and recorded with a purpose-built software 
(Data Acquisition System) written in LabVIEW® (National 
Instruments, Austin, TX, USA). Volume was then calcu-
lated by numerical integration of airflow. The PV curves 
where peak airway pressure remains stable and near to 
20 cm H2O were fitted with a sigmoidal model (Eq. 1):
where Pel is the elastic pressure, V is the Volume, and a, 
b, c and d are the coefficients of the model, obtained by 
nonlinear fitting with the Levenberg–Marquardt method. 
The point of maximal compliance (PMC) is equivalent to 
the parameter c of this model and was estimated for each 
animal.
Statistical analysis
Statistical analysis was carried out using the GraphPad 
Prism software (San Diego, CA, USA). P values were 
calculated by unpaired Student’s t test, except for PMC 
calculated with Wilcoxon rank sum test. Results are 
expressed as mean ± SEM (median (IQR)). The level of 
significance was set at P ≤ 0.05.
Results
Expression of αD mRNA transcripts is increased in the lung 
in Plasmodium berghei infection
Transcripts for αD in the lungs of wild type mice were 
examined in the basal state and after infection with P. 
berghei. RT-PCR analysis of mRNA extracted from lungs 
of naïve, uninfected animals demonstrated a low level of 
the αD transcript. The expression of αD increased dramat-
ically at 7 and 10 days after infection with P. berghei and 
approached levels detected in the spleen (Fig.  1), where 
αDβ2 integrin is constitutively expressed [50].
Disrupted alveolar‑capillary membrane barrier 
function and alveolar inflammation are ameliorated 
in αDβ2‑deficient mice
Infection with P. berghei, induces alveolar-capillary bar-
rier disruption and lung edema in mice of several back-
grounds [33–37]. Consistent with these observations 
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protein concentration in BALF samples (Fig.  2a), lung 
weight (Fig.  2b), and lung endothelial permeability as 
measured by extravasation of Evans Blue dye (Fig.  2c) 
were increased in wild type mice infected with P. berghei. 
Similar alterations in these variables are seen in murine 
acute lung injury induced by other insults [62] and are 
key correlates of disrupted alveolar-capillary barrier 
integrity and increased permeability pulmonary oedema, 
which are cardinal features of clinical and experimental 
ARDS [30, 31, 62]. Each variable was improved to near 
basal levels in αD−/− mice infected with P. berghei com-
pared to measurements in infected wild type animals 
(Fig. 2a–c), indicating that alveolar-capillary barrier dis-
ruption is ameliorated in mice deficient in αDβ2. Focal 
haemorrhages, which were scattered throughout the 
inflamed lung parenchyma of P. berghei-infected wild 
type mice (Fig.  3), were less frequent in αDβ2-deficient 
mice. The latter finding is also consistent with ameliora-
tion of endothelial leakiness in αD−/− animals.
Accumulation of leukocytes was found in the lungs of 
wild type mice infected with P. berghei (Fig.  3). Never-
theless, increased leukocyte numbers was not detected 
in the alveolar spaces as demonstrated by cell counts in 
BALF samples (total BALF cell numbers in wild type P. 
berghei-infected mice 4.86 × 105 ± 0.7502 cells/mL com-
pared to 4.165 × 105 ± 0.4847 cells/mL in uninfected wild 
type controls P = 0.4863). This finding, and microscopic 
analysis (Figs.  3, 4), indicated that the primary accumu-
lation of leukocytes is in the alveolar vessels and inter-
stitium rather than in the alveolar space under these 
conditions. This distribution of inflammatory cells in the 
lungs was also reported in previous studies of P. berghei-
infected C57BL/6 mice [33]. To better characterize 


























Fig. 1 αD mRNA expression is increased in the lungs of mice infected 
with Plasmodium berghei ANKA. Infected wild type were sacrificed 
7 or 10 days later. Lungs were removed, processed and reverse 
transcribed. Transcripts for αD were quantified by real‑time quanti‑
tative PCR and normalized to the levels of hypoxanthine guanine 
phosphoribosyl transferase (HRPT). Expression of αD in spleen was 
used as a positive control. Each bar represents the mean ± SEM of 
determinations in tissue from 5 animals. *P ≤ 0.04, **P ≤ 0.001 by 
student’s t test



































































Fig. 2 Alveolar‑capillary barrier disruption and increased perme‑
ability pulmonary are ameliorated in αDβ2‑deficient mice infected 
with Plasmodium berghei ANKA. Infected wild type (αD
+/+) and αDβ2‑
deficient (αD
−/−) were study 7 days after infection. Bronchoalveolar 
lavage fluid (BALF) was performed. a Total protein concentration 
was measured in BALF samples using a BCA protein determina‑
tion assay. b A second group of animals was sacrificed without 
BALF and the lungs were removed and weighed immediately after 
sacrifice. c In a third group of αD
+/+ and αD
−/− mice, Evans Blue Dye 
(2 %, 0.2 mL) was injected intravenously. The animals were sacri‑
ficed 1 h later, and Evans Blue Dye concentration in the lung tissue. 
Each bar in panels a–c indicates the mean ± SEM. of determina‑
tions from 5 animals.#P ≤ 0.05 compared to the respective control 
group;  P ≤ 0.05 compared to αD+/+ infected mice
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leukocytes that accumulated in the alveolar interstitium of 
mice infected with P. berghei, lung sections from infected 
animals were stained with mAb F4/80 and high frequency 
of positive cells was observed (Fig. 4). This indicates that 
macrophages and monocytes are the major leukocyte 





























Fig. 3 Vascular and interstitial inflammation are key components of MA‑ARDS in Plasmodium berghei ANKA‑infected mice. After staining with 
haematoxylin‑eosin, the sections were examined by optical microscopy (×200 magnification). The scale bars indicate 50 µm. a Lung tissue from 
an uninfected αD
+/+ mouse. b Lung section from an uninfected αD
−/− animal. c Lung tissue from an infected wild type αD
+/+ animal. The arrowhead 
identifies adherent leukocytes in a pulmonary vessel, indicating vascular inflammation. Diffuse interstitial infiltrates (arrow) and focal haemorrhages 
(asterisks) were also seen. d Lung tissue section from an infected αD
−/− mouse. The features illustrated in a–d are representative of those seen in lung 
tissue from 3 individual mice in each condition. e Lung cellularity was determined by the point counting technique across 20 random, non‑coinci‑
dent microscopic fields at magnification of ×1000, as described in “Methods” section. Each bar represents the mean of determinations in tissue from 
3 animals ± SEM.#P ≤ 0.05 compared to respective control
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animals at 7  days post-infection [63, 64]. In conclusion, 
the findings in this model are similar to descriptions of 
alveolar inflammation and accumulation of monocytes 
and macrophages in alveolar vessels and the interstitium 
in histopathologic specimens from the lungs of patients 
who died with MA-ARDS [3, 21, 25, 28, 29].
Lung cellularity and alveolar leukocyte accumulation 
were dramatically reduced in samples from αD−/− mice 
infected with P. berghei compared to leukocyte accu-
mulation in lungs of infected wild type animals (Fig. 3). 
Consistent with this, the frequency of F4/80-positive 
leukocytes was reduced in αDβ2-deficient mice (Fig.  4). 
In addition, leukocytes adherent to the endothelium of 
pulmonary vessels were reduced in lung sections from 
infected αD−/− mice when compared to sections from 
infected wild type animals (Fig. 3).
To further characterize the decreased cellularity and leu-
kocyte accumulation in the lungs of αD−/− mice, expression 
of VCAM-1, an important ligand for αDβ2 [50, 65, 66] was 
examined. Increased expression of VCAM-1 was observed 
in the lungs of infected animals. Increased VCAM-1 stain-
ing was similar in the αD+/+ and αD−/− genotypes (Fig.  5), 
indicating that expression of this adhesive ligand is not 
altered by the genetic manipulation and suggesting that 
the decrease in leukocyte accumulation in the lungs of 
αD−/− animals (Figs. 3, 4) is due to deficiency of αDβ2.
Inflammatory cytokines are decreased in the lungs 
of αDβ2‑deficient mice infected with Plasmodium berghei
To explore mechanisms related to decreased acute 
lung injury and inflammation in αDβ2-deficient mice 
with experimental MA-ARDS, inflammatory cytokines 
Fig. 4 F4/80‑positive leukocytes accumulate in the alveoli in Plasmodium berghei ANKA‑induced experimental MA‑ARDS and are reduced in αDβ2‑
deficient mice. Lung tissue from αD
+/+ and αD
−/− mice infected with P. berghei was harvested at 7 days after infection. Lung slices were incubated with 
anti‑F4/80 as the primary antibody and HRP‑conjugated secondary antibody. The sections were examined and photographed using an Olympus 
BX41 microscope at ×200 magnification (scale bars 200 mm). a Sections from a control αD+/+ mouse. b Section from a control αD−/− mouse. c Lung 
tissue from an infected αD
+/+ wild type animal. d Section from an infected αD
−/− mouse. The staining patterns shown in a–d are representative of 
those in lung tissue from 3 individual mice for each condition
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were measured in lung homogenates from αD−/− and 
wild type animals collected 7 days after P. berghei infec-
tion. Concentrations of tumour necrosis factor (TNF), 
interleukin-1β (IL-1β), interleukin 6 (IL-6), interleu-
kin-12 (IL-12), monocyte chemotactic protein 1 (MCP-
1), regulated upon activation normal T cell expressed and 
secreted (RANTES), and the murine orthologue of inter-
leukin-8 (IL-8), KC, were increased in lungs of wild type 
αD+/+ animals (Fig. 6). The level of each of these cytokines 
was lower in lung lysates from αDβ2-deficient mice, and 
in some cases was similar to that detected in samples 
from uninfected control animals (Fig. 6).
Airway hyper‑responsiveness and obstruction are induced 
by Plasmodium berghei infection and are improved in P. 
berghei‑infected mice deficient in αDβ2
Although alveolar-capillary membrane injury and MA-
ARDS are the principal features of pulmonary involve-
ment in malaria [21] some patients have evidence for 
airway dysfunction, including cough and airway obstruc-
tion documented by spirometry and pulmonary func-
tion assessment [6, 17]. P. berghei-infected mice showed 
increased airway reactivity that is further increased by 
methacholine challenge at 7 days post-infection (Fig. 7). 
The physiologic alterations in the basal state and the 
enhanced responses to methacholine indicate airway 
hyper-responsiveness [67] in wild type αD+/+ animals 
infected with P. berghei. In infected αD−/− mice airway 
hyper-responsiveness was abrogated in both the basal 
state and after methacholine administration (Fig. 7).
Lung pressure/volume relationships are altered 
by Plasmodium berghei infection
All PV curves were sigmoidal and PMC values were 
lower in infected groups. The expected sigmoidal shape 
of the PV curves indicated a predominance of cyclic 
recruitment at the lower portion of the curve followed 
by a linear region and a predominance of hyperdistention 
in the upper portion (Fig.  8a). In infected mice of both 
genotypes, respiratory system compliance was decreased 
with lower volumes at equal pressures, with an increase 
in hyperdistention and a decrement of the PCM pres-
sure (Fig.  8b). There was a trend toward improvement 
(P  =  0.064) in the PMC values for infected αD−/− mice 
(Fig. 8b).
Discussion
Complicated malaria is a major challenge in management 
of malarial infections, which are dominant global public 
health problems [3]. Pulmonary complications are among 
the most serious and potentially lethal consequences 
of malaria [18, 19, 22], and it is clear that they occur in 
human malarial infections caused by parasite species in 
addition to P. falciparum, including P. vivax and Plasmo-
dium knowlesi [17, 20, 21, 26, 28, 29]. MA-ARDS is the 
most fulminant syndrome of lung involvement in malaria 
[18, 19, 21] and, like ARDS induced by other infectious 
and non-infectious causes [30, 31, 68], is characterized by 
generation of pro-inflammatory cytokines, acute alveo-
lar inflammation, disrupted alveolar capillary membrane 
barrier function, and increased permeability pulmonary 
oedema [19, 21]. Alveolar involvement in MA-ARDS may 
be due in part to organ-specific, local intravascular inflam-
mation and unique events such as release of toxins from 
parasitized RBCs sequestered in the lung [37, 69, 70]. 
Mouse models have the potential to reveal key mecha-
nistic features and common and divergent organ-specific 
responses in MA-ARDS, cerebral malaria, and other com-
plicated malarial syndromes [21, 40, 69]. The present study 
provides additional evidence that acute alveolar injury in 
the Plasmodium berghei ANKA model of MA-ARDS has 
features similar to those in humans with clinical MA-
ARDS [19, 21], including increased permeability pulmo-
nary oedema, vascular and interstitial inflammation with 
accumulation of alveolar monocytes and macrophages, 
focal parenchymal haemorrhages, and pulmonary genera-
tion of cytokines. In addition, AHR and obstruction are 
elements of lung involvement in the P. berghei model, as 
they are in some patients with complicated and uncom-
plicated clinical malaria [6, 17, 19]. Moreover, P. berghei 
infection alters respiratory system elastic components, 
consistent with alveolar and airway inflammation. It is 
important to note that changes in PV relationships are 
late responses to progressive pulmonary involvement, and 
with a more extended time course this tends to worsen. 
Together, these measurements indicate that P. berghei 
infection induces substantial alterations in physiologic 
lung and airway function that accompanies lung inflam-
mation and oedema. Finally, this model was used to exam-
ine regulation of key events in P. berghei-induced lung 
inflammation by an important leukocyte integrin, αDβ2.
(See figure on previous page.) 
Fig. 5 VCAM‑1 expression is increased in the lungs of wild type and αDβ2‑deficient mice after infection. Wild type and αDβ2‑deficient mice were 
infected with PbA and lungs were harvested at sacrifice at 7 days of infection. Lungs from infected wild type animals at day 0 were also obtained and 
handled in the same fashion. Staining for VCAM‑1 was accomplished with a specific fluorescently labelled rat anti‑mouse antibody (red staining). A 
rat anti‑mouse IgG2b was used as an irrelevant control antibody. Nuclei were stained with DAPI. The sections were examined and photographed by 
immunoflourescent microscopy at ×20 magnification (50 μm). The patterns shown in the panels are representative of those seen in samples from 3 
individual animals for each condition
Page 10 of 15de Azevedo‑Quintanilha et al. Malar J  (2016) 15:393 
Fig. 6 Inflammatory cytokines are decreased in the lungs of αDβ2‑deficient mice in Plasmodium berghei ANKA‑induced MA‑ARDS. Wild type and 
αDβ2‑deficient mice were infected with PbA and lungs were harvested at 7 days after infection. Cytokine and chemokine levels were measured in 
the homogenates by ELISA. a TNF. b IL‑12. c IL‑1b. d IL‑6. e MCP‑I. f RANTES. g KC. Each bar indicates the mean ± SEM. of determinations in lung 
samples from 5 individual animals.#P ≤ 0.05 compared to the respective control group; *P ≤ 0.05 compared to infected wild type (αD+/+) mice
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β2 integrins have critical activities in leukocyte biol-
ogy, including regulation of adhesion, targeting and 
accumulation in infected or injured tissue sites, apopto-
sis, activation and inflammatory signalling, and immune 
interactions [42, 44, 45, 71]. Thus, β2 integrins are mem-
bers of a complex fabric of effector molecules that regu-
late leukocyte participation in infectious, inflammatory 
and immune host responses. Integrin αDβ2 is the most 
recently identified β2 integrin [44, 48], and its specific 
contributions to infectious and inflammatory patholo-
gies are largely unexplored. Experiments in this study 
indicate that it has major effector activities in experi-
mental MA-ARDS induced by P. berghei. Expression of 
transcripts coding for the αD subunit were increased in 
the lungs of mice infected with P. berghei. Increased αD 
transcripts may have been due to accumulation of αD-
expressing monocytes or other αD-expressing leukocytes 
from the blood [54], induction of αD expression in resi-
dent alveolar macrophages and other lung myeloid leu-
kocytes [50, 53], or both mechanisms. While this issue 
remains to be resolved, increased expression of αD in the 



















Fig. 7 Plasmodium berghei ANKA infection induces increased airway 
reactivity that is ameliorated in αDβ2‑deficient mice. Infected αDβ2‑
deficient and wild type mice were studied 7 days after infection. 
Uninfected αD
−/− and αD
+/+ animals were also studied as controls. 
Airway hyperreactivity was evaluated by challenge of the animals 
with aerosolized phosphate buffered saline (PBS) followed by metha‑
choline (25 mg/mL in PBS) and is expressed as average enhanced 
pause (Penh). Each bar represents determinations in 10 animals 
(mean ± SEM).#P ≤ 0.05 compared to the respective control group; 
*P ≤ 0.05 compared to infected αD+/+ mice
Fig. 8 Pressure/volume curves are sigmoidal and PMC is decreased in Plasmodium berghei ANKA‑infected mice. Wild type and αD
−/−animals from 
infected and control groups were mechanically ventilated and three PV curves were obtained (RR = 6 breaths/min, PEEP = 0 cm H2O, I:E ratio = 4:1, 
VT = 25–30 mL/kg). The PV curves where peak airway pressure remains stable and near to 20 cm H2O were fitted according to Eq. 1. The curve 
model gives the pressure value at which the respiratory system has maximum compliance. a Upper (dashdot), mean (solid) and lower (dashed) fit‑
ted curves of each group. b The PMC are lower, for infected wild type (P < 0.002) and αD
−/− (P < 0.008) mice compared with respective uninfected 
controls
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lungs of animals with experimental MA-ARDS implies 
upregulation of αDβ2 and that αDβ2 on lung leukocytes has 
important activities in this condition. Of interest, αDβ2 
is increased on the surfaces of leukocytes in the lungs of 
human subjects who died of ARDS triggered by other 
causes [51].
This study used mice with genetic deletion of αD and 
consequent absence of αDβ2 [50] to examine its contri-
butions to the pathophysiology of P. berghei-induced 
MA-ARDS. Specific blocking antibodies against the αD 
subunit or αDβ2 are not commercially or generally avail-
able, making a genetic approach essential to target αDβ2 
while leaving other leukocyte integrins intact [42, 44]. 
This study shows that key determinants of acute lung 
injury were improved in αD−/− animals at 7  days after 
infection. The seven-day time point was chosen because, 
in previous study of severe malaria caused by P. berghei, 
survival curves for wild type and αD−/− mice began to 
diverge at 7  days [50]. In the current experiments, lung 
leukocyte accumulation was reduced in αD−/− at 7  days. 
This finding is consistent with published evidence that 
αDβ2 mediates leukocyte accumulation and monocyte 
migration in tissue inflammation and injury in vivo [55, 
57, 72], and that it mediates macrophage adhesion to tis-
sue ligands [50] and purified protein targets [73] in vitro. 
In parallel, pulmonary vascular leak, evaluated by Evans 
Blue Dye extravasation [21, 62, 74], and increased perme-
ability alveolar oedema, assayed by BALF protein con-
centration and lung weight [21, 62], were ameliorated in 
αDβ2-deficient animals. Thus, key determinants of the 
pathology and pathophysiology of acute alveolar injury 
in experimental and clinical ARDS [30, 62, 68] were 
improved in αD−/− animals in comparison to assessment 
of these variables in wild type mice. Furthermore, there 
was a similar pattern of improvement in airway func-
tion in αDβ2-deficient compared to wild type mice. AHR 
has not previously been examined in rodent models of 
malaria-induced pulmonary involvement. While airway 
hyperreactivity is not a prominent feature of ARDS trig-
gered by sepsis and other common causes of ARDS [31, 
68], cough, other symptoms of airway obstruction, and 
physiologic evidence for small airway narrowing and 
reactivity have been detected in patients with malaria [6, 
7, 17, 19]. These findings suggest that airway dysfunction 
may contribute to the pathophysiology of MA-ARDS. 
Improvement in airway function in αD−/− mice indicates 
that airway inflammation is a mechanism of airway dys-
function in the P. berghei model. A trend in improvement 
was found in PV relationships in αD−/− mice, although this 
was not statistically significant.
Chemokine and cytokine levels were also reduced 
in the lungs of infected αD−/− mice compared to the 
levels in pulmonary tissue from wild type mice with 
MA-ARDS. This may be a key mechanism in improved 
alveolar inflammation, reduced alveolar-capillary leak, 
and reduction in alveolar oedema in αDβ2-deficient 
animals. Pro-inflammatory cytokines, including IL-1β, 
TNF, IL-8/KC, and others, are synthesized by alveolar 
macrophages and monocytes and are thought to drive 
alveolar inflammation and injury in experimental and 
clinical ARDS [30, 31, 68]. Cytokine imbalance is pro-
posed to be a feature of the pathophysiology of clinical 
MA-ARDS [19]. In the studies reported here, intrapul-
monary IL-1β, TNF, and KC were substantially reduced 
in infected αD−/− mice. Similarly, IL-12 and RANTES, 
which have pleiotropic activities in inflammation, were 
also reduced, as was MCP-1, which recruits monocytes 
to the lungs [75, 76]. Thus, reduced pro-inflammatory 
cytokines in infected αD−/− mice may in part account for 
reductions in the vascular and interstitial inflammation 
in these animals. Reductions in key cytokines may also 
account for improvement in alveolar-capillary barrier 
integrity and reduced leak of protein and fluid into the 
alveolar spaces of αDβ2-deficient mice compared to wild 
type mice with MA-ARDS. IL-1β and TNF are major 
agonists for endothelial VE cadherin internalization and 
endothelial barrier disruption in models of inflamma-
tory injury, including experimental ARDS [77–79]. TNF 
and IL-1β were reduced to baseline levels in the lungs of 
infected αD−/− mice, potentially contributing to improved 
barrier function. Of note, a reduced systemic cytokine 
levels was also found in αDβ2-deficient mice infected 
with P. berghei in earlier analysis of this model [50]. The 
molecular events that mediate altered chemokine and 
cytokine levels in αDβ2-deficient mice are not yet com-
pletely defined. Nevertheless, in studies with human 
monocytes were found that engagement of αDβ2 with 
activating antibodies or specific ligands induces outside-
in signaling to chemokine and cytokine synthetic path-
ways [51]. These evolving observations indicate that 
αDβ2, like other β2 integrins [80, 81], is a key regulator 
of chemokine and cytokine gene expression in myeloid 
leukocytes.
Conversely, the release of cytokines, leads to cell activa-
tion and increased expression of adhesion molecules such 
as integrins and immunoglobulins superfamily members 
[82–84]. Several studies show the role of integrins in 
development pulmonary oedema, including beta inte-
grins [85]. The main functions of CD11/CD18 integrins 
are adhesion and migration [86, 87], and previous studies 
showed that VCAM-1 is an important adhesion receptor 
in models of experimental [88] and human malaria [89–
91] and is a potential ligand for leukocytes and PRBC, 
in cytoadherence processes that lead to obstruction of 
the microcirculation. This work demonstrate that the 
absence of CD11d integrin does not interfere in VCAM-1 
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expression, and suggest that the effects described in 
this work are due to an increased expression of CD11d 
integrin and not by a lack of its ligand. This study with 
VCAM-1 suggests increased endothelial activation dur-
ing P. berghei infection, however, more experiments are 
necessary to better characterize this activation.
Conclusion
In conclusion, this report demonstrate that integrin 
αDβ2 is an important effector molecular in the inflam-
matory manifestations of severe P. berghei infection, 
including increased alveolar-capillary membrane perme-
ability, alveolar monocyte and macrophage accumula-
tion, and lung oedema, and that it is a key determinant 
of critical pathophysiologic events in this model of MA-
ARDS. Blunting of acute lung injury in αDβ2-deficient 
mice likely contributes to the early survival advantage of 
αD−/− animals in lethal P. berghei infection, although they 
ultimately succumb to progressive hyperparasitaemia 
and severe malarial anaemia [50]. Other specific integ-
rin heterodimers on a variety of cell types [41–43] may 
also contribute to the pathobiology of malarial infection, 
although this has been examined in only a limited fash-
ion [92, 93]. Because of their diverse activities in inflam-
matory cell adhesion, accumulation, and signalling, αDβ2 
and other leukocyte integrins may have pivotal roles in 
MA-ARDS, cerebral malaria and other complications 
of experimental and clinical malarial infection [44, 45, 
71]. Dissection of the roles of leukocyte integrins will 
likely provide new insights into the innate and adaptive 
immune fabric of the host responses to Plasmodium, 
and increased understanding of cell- and organ-specific 
events in malarial inflammation.
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